AID in aging and autoimmune diseases

References

• Okazaki I. M., Kinoshita K., Muramatsu M., Yoshikawa K., Honjo T.. The AID enzyme induces class switch recombination in fibroblasts. Nature. 2002; 416:340–345.
   PubMed Web of Science ®Google Scholar
• Yoshikawa K., Okazaki I. M., Eto T., . AID enzyme-induced hypermutation in an actively transcribed gene in fibroblasts. Science. 2002; 296:2033–2036.
   PubMedGoogle Scholar
• Muramatsu M., Kinoshita K., Fagarasan S., . Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell. 2000; 102:553–563.
   PubMed Web of Science ®Google Scholar
• Revy P., Muto T., Levy Y., . Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell. 2000; 102:565–575.
   PubMed Web of Science ®Google Scholar
• Stavnezer J., Guikema J. E., Schrader C. E.. Mechanism and regulation of class switch recombination. Annu. Rev. Immunol.. 2008; 26:261–292.
   PubMed Web of Science ®Google Scholar
• Pone E. J., Zan H., Zhang J., Al-Qahtani A., Xu Z., Casali P.. Toll-like receptors and B-cell receptors synergize to induce immunoglobulin class-switch DNA recombination: relevance to microbial antibody responses. Crit. Rev. Immunol.. 2010; 30:1–29.
   PubMedGoogle Scholar
• Frasca D., Blomberg B. B.. Aging affects human B cell responses. J. Clin. Immunol.. 2011; 31:430–435.
   PubMed Web of Science ®Google Scholar
• Frasca D., Diaz A., Romero M., . Intrinsic defects in B cell response to seasonal influenza vaccination in elderly humans. Vaccine. 2010; 28:8077–8084.
   PubMed Web of Science ®Google Scholar
• Frasca D., Diaz A., Romero M., . Unique biomarkers for B-cell function predict the serum response to pandemic H1N1 influenza vaccine. Int. Immunol.. 2012; 24:175–182.
   PubMed Web of Science ®Google Scholar
• Frasca D., Landin A. M., Lechner S. C., . Aging down-regulates the transcription factor E2A, activation-induced cytidine deaminase, and Ig class switch in human B cells. J. Immunol.. 2008; 180:5283–5290.
   PubMed Web of Science ®Google Scholar
• Muramatsu M., Nagaoka H., Shinkura R., Begum N. A, Honjo T.. Discovery of activation-induced cytidine deaminase, the engraver of antibody memory. Adv. Immunol.. 2007; 94:1–36.
   PubMedGoogle Scholar
• Rada C., Williams G. T., Nilsen H., . Immunoglobulin isotype switching is inhibited and somatic hypermutation perturbed in UNG-deficient mice. Curr. Biol.. 2002; 12:1748–1755.
   PubMed Web of Science ®Google Scholar
• Levy J., Espanol-Boren T., Thomas C., . Clinical spectrum of X-linked hyper-IgM syndrome. J. Pediatr.. 1997; 131:47–54.
   PubMed Web of Science ®Google Scholar
• Lougaris V., Badolato R., Ferrari S., Plebani A.. Hyper immunoglobulin M syndrome due to CD40 deficiency: clinical, molecular, and immunological features. Immunol. Rev.. 2005; 203:48–66.
   PubMed Web of Science ®Google Scholar
• Durandy A.. Hyper-IgM syndromes: a model for studying the regulation of class switch recombination and somatic hypermutation generation. Biochem. Soc. Trans.. 2002; 30:815–818.
   PubMedGoogle Scholar
• Ferrari S., Giliani S., Insalaco A., . Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM. Proc. Natl. Acad. Sci. USA. 2001; 98:12614–12619.
   PubMed Web of Science ®Google Scholar
• Imai K., Zhu Y., Revy P., . Analysis of class switch recombination and somatic hypermutation in patients affected with autosomal dominant hyper-IgM syndrome type 2. Clin. Immunol.. 2005; 115:277–285.
   PubMed Web of Science ®Google Scholar
• Imai K., Slupphaug G., Lee W. I., . Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination. Nat. Immunol.. 2003; 4:1023–1028.
   PubMedGoogle Scholar
• Meyers G., Ng Y. S., Bannock J. M., . Activation-induced cytidine deaminase (AID) is required for B-cell tolerance in humans. Proc. Natl. Acad. Sci. USA. 2011; 108:11554–11559.
   PubMed Web of Science ®Google Scholar
• Gronwall C., Vas J., Silverman G. J.. Protective roles of natural IgM antibodies. Front. Immunol.. 2012; 3:66.
   PubMed Web of Science ®Google Scholar
• Jiang C., Foley J., Clayton N., . Abrogation of lupus nephritis in activation-induced deaminase-deficient MRL/lpr mice. J. Immunol.. 2007; 178:7422–7431.
   PubMed Web of Science ®Google Scholar
• Jiang C., Zhao M. L., Scearce R. M., Diaz M.. Activation-induced deaminase-deficient MRL/lpr mice secrete high levels of protective antibodies against lupus nephritis. Arthritis Rheum.. 2011; 63:1086–1096.
   PubMed Web of Science ®Google Scholar
• Mannoor K., Matejuk A., Xu Y., Beardall M., Chen C.. Expression of natural autoantibodies in MRL-lpr mice protects from lupus nephritis and improves survival. J. Immunol.. 2012; 188:3628–3638.
   PubMedGoogle Scholar
• Frasca D., Van der Put E., Riley R. L., Blomberg B. B.. Reduced Ig class switch in aged mice correlates with decreased E47 and activation-induced cytidine deaminase. J. Immunol.. 2004; 172:2155–2162.
   PubMedGoogle Scholar
• Gibson K. L., Wu Y. C., Barnett Y., . B-cell diversity decreases in old age and is correlated with poor health status. Aging Cell. 2009; 8:18–25.
   PubMed Web of Science ®Google Scholar
• Quong M. W., Romanow W. J., Murre C.. E protein function in lymphocyte development. Annu. Rev. Immunol.. 2002; 20:301–322.
   PubMed Web of Science ®Google Scholar
• Sayegh C. E., Quong M. W., Agata Y., Murre C.. E-proteins directly regulate expression of activation-induced deaminase in mature B cells. Nat. Immunol.. 2003; 4:586–593.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S., Goldstein I., Fudim E., . Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurines. Gut. 2009; 58:396–403.
   PubMedGoogle Scholar
• Poppe D., Tiede I., Fritz G., . Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J. Immunol.. 2006; 176:640–651.
   PubMed Web of Science ®Google Scholar
• Johnston A., Gudjonsson J. E., Sigmundsdottir H., Ludviksson B. R., Valdimarsson H.. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin. Immunol.. 2005; 114:154–163.
   PubMed Web of Science ®Google Scholar
• Tracey D., Klareskog L., Sasso E. H., Salfeld J. G., Tak P. P.. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther.. 2008; 117:244–279.
   PubMed Web of Science ®Google Scholar
• Deutsch D. E., Olson A. D., Kraker S., Dickinson C. J.. Overwhelming varicella pneumonia in a patient with Crohn's disease treated with 6-mercaptopurine. J. Pediatr. Gastroenterol. Nutr.. 1995; 20:351–353.
   PubMed Web of Science ®Google Scholar
• Korelitz B. I., Fuller S. R., Warman J. I., Goldberg M. D.. Shingles during the course of treatment with 6-mercaptopurine for inflammatory bowel disease. Am. J. Gastroenterol.. 1999; 94:424–426.
   PubMedGoogle Scholar
• Ferrucci L., Corsi A., Lauretani F., . The origins of age-related proinflammatory state. Blood. 2005; 105:2294–2299.
   PubMed Web of Science ®Google Scholar
• Franceschi C., Capri M., Monti D., . Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech. Ageing Dev.. 2007; 128:92–105.
   PubMed Web of Science ®Google Scholar
• Franceschi C., Valensin S., Bonafe M., . The network and the remodeling theories of aging: historical background and new perspectives. Exp. Gerontol.. 2000; 35:879–896.
   PubMed Web of Science ®Google Scholar
• Harris T. B., Ferrucci L., Tracy R. P., . Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am. J. Med.. 1999; 106:506–512.
   PubMed Web of Science ®Google Scholar
• Wikby A., Nilsson B. O., Forsey R., . The immune risk phenotype is associated with IL-6 in the terminal decline stage: findings from the Swedish NONA immune longitudinal study of very late life functioning. Mech. Ageing Dev.. 2006; 127:695–704.
   PubMed Web of Science ®Google Scholar
• Andrisani G., Frasca D., Romero M., . Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-alpha agents: Effects of combined therapy with immunosuppressants. J. Crohns Colitis. 2012 in press.
   Google Scholar
• Murasko D. M., Bernstein E. D., Gardner E. M., . Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp. Gerontol.. 2002; 37:427–439.
   PubMed Web of Science ®Google Scholar
• Skowronski D. M., Tweed S. A., De Serres G.. Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant?. J. Infect. Dis.. 2008; 197:490–502.
   PubMed Web of Science ®Google Scholar
• Ito T., Suzuki Y., Mitnaul L., . Receptor specificity of influenza A viruses correlates with the agglutination of erythrocytes from different animal species. Virology. 1997; 227:493–499.
   PubMed Web of Science ®Google Scholar
• Frasca D., Diaz A., Romero M., Landin A. M., Blomberg B. B.. Age effects on B cells and humoral immunity in humans. Ageing Res. Rev.. 2011; 10:330–335.
   PubMed Web of Science ®Google Scholar
• Cullen G., Bader C., Korzenik J. R., Sands B. E.. Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease. Gut. 2012; 61:385–391.
   PubMed Web of Science ®Google Scholar
• Gelinck L. B., van der Bijl A. E., Beyer W. E., . The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann. Rheum. Dis.. 2008; 67:713–716.
   PubMed Web of Science ®Google Scholar
• Molnar T., Farkas K., Jankovics I., . Appropriate response to influenza A (H1N1) virus vaccination in patients with inflammatory bowel disease on maintenance immunomodulator and/or biological therapy. Am. J. Gastroenterol.. 2011; 106:370–372.
   PubMedGoogle Scholar
• Macdonald T. T., Monteleone G.. Immunity, inflammation, and allergy in the gut. Science. 2005; 307:1920–1925.
   PubMed Web of Science ®Google Scholar
• ACIP. Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins for persons with altered immunocompetence. MMWR Recomm. Rep.. 1993; 42:1–18.
   Google Scholar
• Rahier J. F., Yazdanpanah Y., Viget N., Travis S., Colombel J. F.. Review article: influenza A (H1N1) virus in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther.. 2010; 31:5–10.
   PubMedGoogle Scholar
• Sands B. E., Cuffari C., Katz J., . Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm. Bowel Dis.. 2004; 10:677–692.
   PubMed Web of Science ®Google Scholar
• Melmed G. Y., Ippoliti A. F., Papadakis K. A., . Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am. J. Gastroenterol.. 2006; 101:1834–1840.
   PubMed Web of Science ®Google Scholar
• Sambhara S., McElhaney J. E.. Immunosenescence and influenza vaccine efficacy. Curr. Top. Microbiol. Immunol.. 2009; 333:413–429.
   PubMedGoogle Scholar
• Zhou X., McElhaney J. E.. Age-related changes in memory and effector T cells responding to influenza A/H3N2 and pandemic A/H1N1 strains in humans. Vaccine. 2011; 29:2169–2177.
   PubMed Web of Science ®Google Scholar
• Noronha A. M., Liang Y., Hetzel J. T., . Hyperactivated B cells in human inflammatory bowel disease. J. Leukoc. Biol.. 2009; 86:1007–1016.
   Google Scholar
• Lodes M. J., Cong Y., Elson C. O., . Bacterial flagellin is a dominant antigen in Crohn disease. J. Clin. Invest.. 2004; 113:1296–1306.
   PubMed Web of Science ®Google Scholar
• Frasca D., Romero M., Diaz A., . A molecular mechanism for TNF-alpha-mediated downregulation of B cell responses. J. Immunol.. 2012; 188:279–286.
   PubMed Web of Science ®Google Scholar